3-(4-tert-butylphenyl)-7-hydroxy-4H-chromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 3-(4-tert-butylphenyl)-7-hydroxy-4H-chromen-4-one
• 英文别名: 3-(4-Tert-butylphenyl)-7-hydroxy-chromen-4-one；3-(4-tert-butylphenyl)-7-hydroxychromen-4-one
• 化学式: C₁₉H₁₈O₃
• 分子量: 294.35
• InChiKey: SLSSQYSGYAVOAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-tert-butylphenyl)-7-hydroxy-4H-chromen-4-one 在 sodium hydride 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 3-[4-(1,1-dimethylethyl)phenyl]-7-[4-(piperazin-1-yl)butoxy]-4H-1-benzopyran-4-one bis[hydrochloride]
  参考文献：
  名称：

  Novel Basic Isoflavones as Inhibitors of Bone Resorption

  摘要：

  A number of aminoalkoxy analogues of ipriflavone (=7-(1-methylethoxy)isoflavone) were prepared and examined for their capacity to inhibit bone resorption induced by bovine parathyroid hormone fragment 1 - 34. Good-to-high activities were found for 7-(aminoalkoxy)isoflavone. analogues. Their activity was influenced by a number of structural features, among which the length of the basic side chain, the basicity of the amino group, and the nature and position of substituents on the 3-phenyl ring. 4'-(Aminoalkoxy)ipriflavone derivatives were less active.

  DOI：

  10.1002/1522-2675(20010815)84:8<2417::aid-hlca2417>3.0.co;2-n
• 作为产物：
  描述：

  3-iodo-7-((tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 甲苯 为溶剂， 反应 2.0h， 生成 3-(4-tert-butylphenyl)-7-hydroxy-4H-chromen-4-one
  参考文献：
  名称：

  Inhibition of PI3 Kinase Gamma Enzyme by Novel Phenylpyrazoles

  摘要：

  DOI：

  10.5012/bkcs.2013.34.9.2829

文献信息

• [EN] ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ANTI-VIRAUX, COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES D'UTILISATION DE CES DERNIERS
  申请人：KINETA INC

  公开号：WO2016073947A1

  公开（公告）日：2016-05-12

  Disclosed herein are compounds and pharmaceutical compositions, and uses thereof for the treatment of viral infections, including RNA viral infections. The compounds, pharmaceutical compositions, and methods disclosed herein can relate to chromenone drug candidate compounds that modulate innate immunity along the RLR-IRF3 axis. These compounds activate innate immune signaling downstream of numerous viral countermeasures and are a unique addition to conventional antiviral compounds in development or on the market. These compounds possess broad spectrum in vitro activity against diverse RNA viruses including the respiratory pathogens influenza, RSV, and hCoV, with EC50 values in the low nanomolar range. Potent in vitro activity is also demonstrated against systemic and emerging viruses including Dengue and Ebola.

  披露了用于治疗病毒感染，包括RNA病毒感染的化合物和药物组合物及其用途。所披露的化合物、药物组合物和方法可能与调节RLR-IRF3轴上先天免疫的色酮类药物候选化合物相关。这些化合物激活了针对多种病毒对策的先天免疫信号传导，并且是对开发中或市场上的传统抗病毒化合物的独特补充。这些化合物在试管中对包括呼吸道病原体流感、呼吸道合胞病毒和人类冠状病毒在内的多种RNA病毒具有广泛的谱系活性，EC50值在低纳摩尔范围内。还展示了针对系统和新兴病毒（包括登革热和埃博拉）的强大试管内活性。
• ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：KINETA, INC.

  公开号：US20160122312A1

  公开（公告）日：2016-05-05

  Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of viral infection, including RNA viral infection, as well as compounds, pharmaceutical compositions, and methods for modulating the RIG-I pathway in a subject and/or in cells. These compounds are isoflavone derivatives, typically substituted at the 3-position with an aryl group and at the 7-position with a heterofunctional group.

  本文披露了化合物、制药组合物以及治疗病毒感染的方法，包括RNA病毒感染的方法，以及在受体内和/或细胞中调节RIG-I通路的化合物、制药组合物和方法。这些化合物是异黄酮衍生物，通常在3位上用芳基基团取代，在7位上用杂功能基团取代。
• Synthesis, antimycobacterial evaluation and pharmacophore modeling of analogues of the natural product formononetin
  作者：Peggoty Mutai、Elumalai Pavadai、Ian Wiid、Andile Ngwane、Bienyameen Baker、Kelly Chibale

  DOI：10.1016/j.bmcl.2015.04.064

  日期：2015.6

  The synthesis and antimycobacterial activity of formononetin analogues is hereby reported. Formononetin and its analogue 11E showed 88% and 95% growth inhibition, respectively, against the H37Rv strain of Mycobacterium tuberculosis. Pharmacophore modeling studies indicated that the presence of a hydroxyl group in formononetin and its analogues, is crucial for maintaining activity. (C) 2015 Elsevier Ltd. All rights reserved.
• [EN] ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ANTI-VIRAUX, COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES D'UTILISATION CORRESPONDANTES
  申请人：KINETA INC

  公开号：WO2015009812A3

  公开（公告）日：2015-03-19
• ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Kineta, Inc.

  公开号：EP3021843A2

  公开（公告）日：2016-05-25